Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The observations are procedural in nature and will be responded to within the stipulated time
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Subscribe To Our Newsletter & Stay Updated
